Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span treatment duration, mechanistic biology, and diagnostics. A planned secondary analysis of the BALANCE RCT indicates seven days of antibiotics suffice for most bloodstream infections regardless of day-7 procalcitonin levels. Mechanistically, VNN1 drives inflammation and oxidative stress via NF-κB/PPARγ, and a meta-analysis shows circulating microRNAs have moderate diagnostic accuracy but require standardization.
Research Themes
- Antibiotic stewardship and optimal duration in bloodstream infection
- Mechanistic targets modulating inflammatory and oxidative pathways in sepsis
- Molecular diagnostics: circulating microRNAs and evidence standardization
Selected Articles
1. Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the BALANCE Trial.
In a planned secondary analysis of the multicenter BALANCE RCT, day-7 procalcitonin ≥250 pg/mL identified higher-risk patients, yet extending antibiotics to 14 days did not reduce 90-day mortality versus 7 days. Seven days appears sufficient for most bloodstream infections regardless of residual PCT levels.
Impact: Directly informs antibiotic stewardship by challenging biomarker-driven treatment extension. Uses randomized-trial infrastructure to address a common clinical dilemma.
Clinical Implications: Do not extend antibiotics beyond seven days solely due to elevated day-7 PCT in stable bloodstream infection patients; prioritize clinical trajectory and source control.
Key Findings
- Day-7 PCT ≥250 pg/mL was associated with higher 90-day mortality: 21.6% vs 6.2% (ARD 15.5%; 95% CI 3.6%-27.5%).
- Among patients with high PCT, 7 vs 14 days of antibiotics showed no mortality difference (ARD -19.9%; 95% CI -1.7 to 41.7).
- PCT measurements were blinded to clinicians and did not influence treatment assignment.
- High PCT patients were older with more comorbidities and more community-acquired bacteremia.
Methodological Strengths
- Planned secondary analysis nested within a multicenter RCT framework
- Biomarker assays blinded to clinicians with 90-day follow-up
- Prespecified mortality outcome using robust adjudication
Limitations
- Modest sample size (n=125) limits precision in subgroup estimates
- Non-randomized comparison by PCT strata may allow residual confounding
- Single time-point PCT threshold may not capture trajectory
Future Directions: Prospective trials integrating dynamic PCT trajectories into adaptive, early-stop antibiotic algorithms and evaluating source-specific subgroups.
IMPORTANCE: The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) trial showed that 7 days of antibiotics was noninferior to 14 days among patients with bacteremia. However, it is unknown whether patients with high serum procalcitonin (PCT) level at day 7 of therapy would benefit from a prolonged treatment course. OBJECTIVE: To investigate whether an elevated serum PCT level at day 7 of bacteremia was associated with increased mortality among patients treated with 7 vs 14 days of antibiotics. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a planned secondary analysis of the BALANCE trial from 2014 to 2023, a multicenter randomized clinical trial where serum was collected on day 7 of bacteremia and patients were followed up for 90 days after study enrollment. Serum samples were collected from patients 7 days after initiation of antibiotics; PCT levels were later quantified by an antibody-based assay and therefore were not available to clinicians. Data were analyzed from January to June 2025. INTERVENTION: Patients were randomized to receive either 7 or 14 days of antibiotics. Antibiotic selection, dosing, and route were at the discretion of the treating team. MAIN OUTCOMES AND MEASURES: The primary outcome was defined as death from any cause within 90 days of the positive index blood culture result. Secondary outcomes included death by any cause while admitted to the ICU, death by any cause while admitted to the hospital, number of days alive and not admitted to the ICU within 28 days of the index positive blood culture, number of days alive and not admitted to hospital within 28 days of the index positive blood culture, and the duration of mechanical ventilation. RESULTS: A total of 125 patients (median age 63, [IQR, 58-79] years; 80 [64.0%] male) were included in this study. Sixty-five participants (52%) had low PCT levels (<250 pg/mL) and 60 (48%) had high PCT levels (≥250 pg/mL) on day 7. The high PCT group was older, had more comorbidities, and had a higher prevalence of community-acquired bacteremia. Ninety-day mortality was higher in the high vs low PCT group: 21.6% (13 of 60) vs 6.2% (4 of 65) (absolute risk difference [ARD] 15.5%; 95% CI, 3.6%-27.5%). Among patients with high PCT level, 90-day mortality was not different among participants with 7 vs 14 days of antbiotics (ARD, -19.9%; 95% CI, -1.7 to 41.7). CONCLUSIONS AND RELEVANCE: In this cohort study, elevated PCT level on day 7 was associated with increased 90-day mortality. However, prolonging antibiotics beyond 7 days was not associated with improved mortality in patients with a residually high PCT level. Seven days of antibiotics appears sufficient for most patients with bloodstream infections independent of day 7 serum PCT level.
2. VNN1 aggravates sepsis by promoting inflammation and oxidative stress through PPARγ signaling VNN1 in sepsis.
VNN1 is upregulated in human sepsis and in murine CLP, and genetic deficiency of VNN1 improves survival and organ function by dampening inflammation and oxidative stress via NF-κB/PPARγ signaling. These data nominate VNN1 as both a mechanistic driver and a potential therapeutic target and prognostic biomarker.
Impact: Reveals a novel mechanistic axis (VNN1–NF-κB/PPARγ) that modulates sepsis severity, integrating human data with genetic loss-of-function in vivo.
Clinical Implications: VNN1 could serve as a prognostic biomarker and a drug target; pharmacologic inhibition or pathway modulation may attenuate inflammatory and oxidative injury in sepsis.
Key Findings
- VNN1 expression is elevated in sepsis patients and correlates positively with inflammatory cytokines.
- VNN1 levels increase in a CLP mouse model; VNN1 knockout improves survival and organ function.
- Inflammation and oxidative stress markers are reduced in VNN1-deficient mice.
- Mechanistic link implicates NF-κB/PPARγ signaling in VNN1-mediated sepsis exacerbation.
- Higher VNN1 levels in patients associate with poorer prognosis.
Methodological Strengths
- Translational approach combining human observational data with genetic knockout murine CLP model
- Mechanistic interrogation of NF-κB/PPARγ signaling axis
Limitations
- Human cohort size and detailed quantitative data not reported in abstract
- Lack of pharmacologic VNN1 inhibition to complement genetic knockout
- Single-center and preclinical nature limit immediate generalizability
Future Directions: Develop selective VNN1 inhibitors; validate prognostic utility and mechanistic signatures in multicenter human cohorts; test pathway modulation in clinically relevant models.
Vanin-1 (VNN1) is crucial in inflammatory response and oxidative stress (OS), yet its contribution to sepsis remains unidentified. In this study, we investigated the functions of VNN1 in sepsis. Our results indicated VNN1 was elevated in sepsis patients and positively correlated with various cytokines. Meanwhile, VNN1 elevated in a mouse model of sepsis. In VNN1 knockout (KO) mice, VNN1 deficiency improved survival and organ function following CLP-induced sepsis. Furthermore, sepsis-induced inflammation and OS were reduced in VNN1 KO mice. Furthermore, our findings indicated VNN1 deficiency alleviated sepsis by regulating NF-kB/PPARγ pathways. Finally, the results showed VNN1 increased in sepsis patients, and higher VNN1 were associated with a poorer prognosis of sepsis. Our findings revealed a novel molecular mechanism in which VNN1 participated in sepsis by regulating NF-kB/PPARγ. This study offered a new strategy for inhibiting sepsis by targeting VNN1 signaling pathways.
3. MicroRNAs in sepsis diagnosis: A systematic review and meta-analysis toward evidence-based biomarker development.
Across 39 studies, circulating miRNAs yielded pooled sensitivity 0.79, specificity 0.82, and AUROC 0.87 for sepsis diagnosis, but with substantial heterogeneity. Functional subgroup analyses indicated performance varies by biological pathways and methods, underscoring the need for standardized, pathway-specific panels.
Impact: Provides the most up-to-date, methodologically rigorous synthesis of miRNA-based sepsis diagnostics and highlights functional sources of heterogeneity to guide biomarker development.
Clinical Implications: Circulating miRNAs may complement existing tests for early sepsis detection, but clinical adoption requires multicenter validation with standardized protocols and appropriate infected non-septic controls.
Key Findings
- Included 39 studies assessing 59 distinct circulating miRNAs for sepsis diagnosis.
- Pooled sensitivity 0.79 and specificity 0.82 with AUROC 0.87.
- Substantial heterogeneity; performance varied by functional miRNA subgroup and methodological context.
- Highlights need for standardized protocols and inclusion of infected non-septic controls.
Methodological Strengths
- PRISMA 2020 and PRISMA-DTA compliant systematic review with QUADAS-2 risk-of-bias assessment
- HSROC meta-analytic modeling and functional subgroup analyses
Limitations
- Substantial heterogeneity across studies limits generalizability
- Variable patient selection and control groups; many single-center, retrospective designs
- Potential publication and reporting biases typical of biomarker literature
Future Directions: Design multicenter, prospective diagnostic accuracy studies using standardized sampling, normalization, and pathway-specific miRNA panels versus infected non-septic controls.
BACKGROUND: Sepsis diagnosis remains challenging, and conventional biomarkers such as CRP and PCT show limited specificity. Circulating microRNAs (miRNAs) have been investigated as diagnostic biomarkers, but substantial methodological variability across studies has limited the interpretation of current evidence. Previous meta-analyses largely evaluated miRNAs as a single biomarker category, leaving variation across biologically distinct subgroups insufficiently explored. METHODS: Following PRISMA 2020 and PRISMA-DTA 2018 guidelines, we systematically searched PubMed, EMBASE, and Scopus through April 2026. Study quality was assessed using QUADAS-2, and pooled diagnostic performance was analyzed using a hierarchical summary receiver operating characteristic (HSROC) model. Subgroup analyses explored clinical, methodological, and functional sources of heterogeneity. RESULTS: Thirty-nine studies involving 59 distinct miRNAs were included. Pooled sensitivity was 0.79 (95% CI: 0.76-0.82) and specificity was 0.82 (95% CI: 0.78-0.85), with an AUROC of 0.87 (95% CI: 0.84-0.90). Substantial heterogeneity was observed (sensitivity I CONCLUSION: Circulating miRNAs demonstrate moderate diagnostic accuracy for sepsis, with functional subgroup analyses showing differences across biologically distinct miRNA categories. Diagnostic performance appears to vary according to both biological function and methodological context. Substantial heterogeneity limits the generalizability of current evidence. Future multicenter studies using standardized protocols and infected non-septic control groups are needed to determine the clinical utility of pathway-specific miRNA panels.